| Symbol | SVRA |
|---|---|
| Name | SAVARA INC |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 6836 BEE CAVE ROAD, AUSTIN, TX 78746 |
| Telephone | 51285113796 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001160308 |
| Description | None |
Savara Inc. - Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Read moreSavara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Read moreSavara Inc. - Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreSavara Reports Second Quarter 2026 Financial Results and Provides Business Update
Read moreNew Form S-8 - Savara Inc <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0001193125-26-344992 <b>Size:</b> 184 KB
Read moreSavara Inc. - Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Read moreSavara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Read moreLutz Robert Matthew 🟢 acquired 105.0K shares (1 derivative) of Savara Inc (SVRA) at $5.81 Transaction Date: Jul 15, 2026 | Filing ID: 316442
Read more